Topical formulation for binding to dermatological cannabinoid receptors
OwnerJessica KADOinventor
Life of this patent
Estimating the term…
Abstract
A topical cream or ointment is provided that provides for the binding to CB1 and/or CB2 receptors for the soothing of pain, inflammation of smooth muscle, tendons, ligaments, skeletal muscle, endothelial cell, synovial cell, peripheral nerve fibers, reduction of endothelial bruising, promotion of healing of endothelial bruising, and dermatological itch sensation wherein the improvement comprises providing the effect of cannabinoid using plant extracts. A topically administered formulation is also provided for treating anal mucosal inflammation, soothing of pain, inflammation of anal mucosal inflammation; reducing keratinocyte apoptosis; treating viral-associated epithelial damage, treating radiation dermatitis; and treating chemotherapy-induced dermatitis.
Claims10
-10. (canceled)
A topically administered formulation for treating anal mucosal inflammation, soothing of pain, inflammation of anal mucosal inflammation;
- reducing keratinocyte apoptosis;
- treating viral-associated epithelial damage, treating radiation dermatitis;
- treating chemotherapy-induced dermatitis;
- treating dermatologic itch;
- and soothing of pain and inflammation of smooth muscle, tendons, ligaments, skeletal muscle, endothelial cell, synovial cell, or peripheral nerve fibers, reduction of endothelial bruising, or promotion of healing of endothelial bruising using a topical application, wherein the formulation provides for the binding to CB1 and/or CB2 receptors for wherein the improvement comprises providing the effect of cannabinoid using plant extracts.
Dependencies are inferred from the claim text.